STA-9090(Ganetespib) in Metastatic Ocular Melanoma
A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma
Sponsor: Beth Israel Deaconess Medical Center
A PHASE2 clinical study on Ocular Melanoma, this trial is completed. The trial is conducted by Beth Israel Deaconess Medical Center and has accumulated 10 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jul 2018 — Nov 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beth Israel Deaconess Medical Center
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
- Massachusetts General Hospital
- Synta Pharmaceuticals Corp.
For direct contact, visit the study record on ClinicalTrials.gov .